Small molecule antagonists of the Wnt/β-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer.
<h4>Background</h4>Recent evidence suggests that human breast cancer is sustained by a minor subpopulation of breast tumor-initiating cells (BTIC), which confer resistance to anticancer therapies and consequently must be eradicated to achieve durable breast cancer cure.<h4>Methods/...
Main Authors: | Robin M Hallett, Maria K Kondratyev, Andrew O Giacomelli, Allison M L Nixon, Adele Girgis-Gabardo, Dora Ilieva, John A Hassell |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22470504/?tool=EBI |
Similar Items
-
Activation status of Wnt/ß-catenin signaling in normal and neoplastic breast tissues: relationship to HER2/neu expression in human and mouse.
by: Sara Khalil, et al.
Published: (2012-01-01) -
HER-2/neu overexpression in breast cancer
by: Rana S. Aziz, et al.
Published: (2010-10-01) -
HER-2/neu-targeted immunoprevention of breast cancer
by: Sas, Sheena Emm
Published: (2007) -
Carcinosarcoma of Breast with Hormone Receptor and Her2/neu Positivity
by: Deepti Agarwal, et al.
Published: (2016-01-01) -
The epidemiology of Her-2/ neu and P53 in breast cancer
by: Bernstein Jonine L., et al.
Published: (1999-01-01)